PAEDIATRIC HIV CARE
Addressing the challenges of the HIV epidemic in vulnerable populations is central to our mission at ViiV Healthcare of “Leaving no PLHIV behind”. This is particularly true for children and adolescents affected by HIV who have unique needs.
Latest statistics show there are 1.8m children under 15 years of age living with HIV due to obstacles including the availability of HIV testing and diagnosis in children, continued mother-to-child transmission, slow initiation of treatment and poor availability of optimised paediatric formulations of ARVs. Caused by a fragmented paediatric HIV market that hinders launch and uptake of new formulations, drug development for CLHIV lags 8 to 10 years behind that of adults. A lack of market incentives and technical issues in manufacturing has lowered the priority for paediatric drug development.
There are 1.8m children under 15 years of age living with HIV due to obstacles including the availability of HIV testing and diagnosis in children, continued mother-to-child transmission, slow initiation of treatment and poor availability of optimised paediatric formulations of ARVs
As a specialist HIV company, we’re committed to addressing the gaps in paediatric HIV, treatment options and management of care; leading the way with the delivery of solutions to ensure no child living with HIV is left behind. Our unique cross-functional team focuses on delivering optimised age-appropriate formulations, working collaboratively with the paediatric HIV field to establish priorities, and designing and driving novel approaches to ensure access to our paediatric medicines. In parallel, we work closely with the HIV community through Positive Action to build healthcare and community capacity, helping to foster a more effective healthcare service provision for children.
We have a long-standing history in our commitment to making a difference in this space and have been
Crucial to our continued progress in
Research and Development
Our scientists are dedicated to developing
Our collaboration with IMPAACT on the P1093 study enabled us to successfully develop an age-appropriate formulation of
Today, we are involved with several clinical studies that will continue up until 2020, focusing purely on
Click for details about the worldwide registration status of ongoing regulatory filings and registration of
Building on a successful partnership with the Clinton Health Access Initiative (CHAI) and Mylan to develop and introduce a dispersible formulation of ABC/3TC for children, ViiV, CHAI and
Our work is focused on priorities set by the World Health Organisation (WHO)-led Paediatric ARV Drug Optimisation (PADO) group. We also collaborate with other major partners in the HIV community such as the International AIDS Society (IAS) as the founding and major sponsor of the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) – now the IAS platform for Paediatric HIV. The Elizabeth Glazer Paediatrics AIDS Foundation is another of our close partners who we work with to increase access for infants and children.
Working with the Communities
Now over 25 years old, our Positive Action programme supports vulnerable communities around the world. Working alongside our Non-Governmental Organisation (NGO) and Community Based Organisation (CBO) partners, we deliver sustainable projects in communities facing the toughest obstacles in HIV and AIDS. Of significance to our work in addressing the epidemic in infants and children, our Positive Action for Children Fund focusses on supporting local community-based
Our Positive Action for Adolescents and Positive Action for Girls & Women programmes also tackle the barriers that can increase a child’s vulnerability to HIV. By addressing
Find out more about Positive Action here.
 UNAIDS. Fact sheet. Available at http://www.unaids.org/en/resources/fact-sheet. Last accessed: November 2018
 JIAS. Shortening the decade-long gap between adult and